Pfizer Profit Skids on Lipitor Loss

Jan. 31, 2012
Pfizer posted fourth-quarter net income of $1.4 billion, down 50% from the year-ago period.

Pfizer on Tuesday reported that profit and sales fell in the fourth quarter, hit hard by the loss of exclusivity on its blockbuster anti-cholesterol drug Lipitor.

Pfizer Inc., the world's leading drug maker, posted fourth-quarter net income of $1.4 billion, down 50% from the year-ago period.

Excluding exceptional items, adjusted earnings were 50 cents per share, topping the average analyst forecast of 47 cents.

Fourth-quarter revenue fell to $16.7 billion, down 4% from the year-ago period.

For the full year, Pfizer said net income rose 21% from the prior year to $10 billion on revenue up 1% to $67.4 billion.

Ian Read, Pfizer's chairman and chief executive, said 2011 was a year of setting a new direction for the company.

"I am pleased with our 2011 financial performance, which was achieved in the face of a challenging global market and product losses of exclusivity of approximately $5 billion," Read said.

Pfizer's U.S. patent on the cholesterol-lowering medication Lipitor -- the best-selling drug of all-time -- expired on Nov. 30, opening the path to generic competitors for America's most popular medication.

Read said the company boosted its research and development efforts, and has a "next wave of compounds that have shown promise" in the pipeline.

Lipitor was introduced in 1997, and has raked in some $100 billion for Pfizer even in a crowded market that includes various other cholesterol-lowering statins, many of which have already gone generic.

For fourth-quarter 2011, Pfizer's U.S. revenues were $6.3 billion, a decline of 12% from a year earlier.

The share of U.S. sales in total revenues shrank to 38% from 41%, while international revenues rose 3% to $10.4 billion.

In 2012, Read said, Pfizer plans to repurchase about $5 billion in common stock under a recently authorized $10 billion buyback program and to pay more than $6 billion in dividends.

Pfizer lowered its 2012 earnings and revenue forecasts. The company estimates earnings of $2.20 to $2.30 per share, from a prior range of $2.25 to $2.35. Revenue is seen at $60.5 billion to $62.5 billion, instead of the $62.2 billion to $64.7 billion previously forecast.

Copyright Agence France-Presse, 2012

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!